Ivor Caro

Dermatology

275 Cambridge St Ste 402
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.

Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.

Journal: Drug safety

Published: October 10, 2022

Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.

Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.

Journal: ESMO open

Published: September 08, 2022

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

Journal: The Lancet. Oncology

Published: August 04, 2022

Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy.

Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 28, 2022

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 24, 2021

First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma.

First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma.

Journal: Pigment cell & melanoma research

Published: December 14, 2020

Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.

Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.

Journal: The Journal of investigative dermatology

Published: March 02, 2020

Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.

Elevated Levels of BRAFV600 Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma.

Journal: JCO precision oncology

Published: November 01, 2018

Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.

Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.

Journal: Journal of drugs in dermatology : JDD

Published: May 10, 2018

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 14, 2018

Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database.

Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database.

Journal: Journal of drugs in dermatology : JDD

Published: February 21, 2018

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 30, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026